Publications & Presentations

⚯ Click on each item to view


Identification of a GPC3 specific RNA aptamer and its use in cell specific targeted killing of GPC3 expressing tumors. Thompson KM, et al AACR 2021.

Increasing immune cell infiltration in hepatocellular carcinoma tumors using a novel GPC3-targeting aptamer conjugate. McGuire C, et al AACR 2021.

BT200, a novel von Willebrand Factor (vWF) binding aptamer for bleeding disorders. Zhu S, et al TIDES Europe 2021.

Aptamer-Drug Conjugates (ApDC’s): Using the “chemical antibody” to target cancer biomarkers and kill tumor cells. Christina M, Novel Format Conjugates Summit 2022.


© 2022 Guardian Therapeutics. All rights reserved.

Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:

Business Development Inquiries: